QuidelOrtho Corporation (QDEL) stock analysis

Healthcare · Medical Devices

From the 10-K filed 2026-02-19

How it makes money

It earns revenue by selling diagnostic instruments and tests across labs, transfusion medicine, molecular diagnostics, and point of care.

It sells diagnostic products directly to end users and through distributors across more than 140 countries and territories. Customers include hospitals, physician offices, clinical and reference laboratories, blood banks, and donor centers, alongside non-professional over-the-counter channels.

Revenue is categorized across business units including Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics, supplemented by non-core revenue from contract manufacturing and collaborations. Total revenues were $2,730.2 million for the fiscal year ended 2025 and $2,782.9 million for the fiscal year ended 2024, with respiratory products accounting for approximately 15%, 18%, and 24% of total revenues in fiscal years 2025, 2024, and 2023 respectively.

What protects it: the moat

It relies on brand names, proprietary technologies, regulatory approvals, and global commercial infrastructure to protect its market position.

Management claims protections through registered and unregistered brand names, patents, and regulatory clearances across various jurisdictions. It also maintains global manufacturing facilities and direct sales channels to sustain customer relationships.

However, the company explicitly notes risks regarding intense industry competition, potential failure to protect proprietary technology rights, and challenges in obtaining required clearances or approvals for its products from regulatory agencies.

What growth costs

It incurs multi-year optimization costs, capital expenditures, and restructuring charges to streamline operations and support strategic priorities.

In the second quarter of 2025, it launched enterprise-wide cost-reduction and margin improvement initiatives known as the Optimization Plan. Cumulative pre-tax charges to implement this plan are expected to be approximately $100 million through 2027, designed to deliver net cost savings of approximately $50 million.

Additionally, it incurs ongoing reinvestments including research and development, facility rationalization, and procurement sourcing initiatives, alongside strategic shifts such as winding down the U.S. donor screening portfolio and discontinuing development of the SAVANNA platform.

What could damage it

A drop in respiratory product demand or COVID-19 revenue can directly reduce total revenue and profitability.

Fluctuations in respiratory testing demand create direct downward pressure on annual financial results. Because a significant portion of revenue relies on these seasonal and virus-dependent product lines, lower incidence rates or reduced testing volumes shrink total corporate revenues directly.

When respiratory product sales decline, the company faces immediate top-line contraction that may not be fully offset by other testing segments, impacting overall cash flows and operating margins.

About QuidelOrtho Corporation

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

Other companies in Medical Devices